Table 1: Demographics and transplant related variables.

CG ( ) BKVN ( ) AV ( ) value

At baseline
 Recipient age (years) 50 ± 1044 ± 2147 ± 10ns
 Donor age (years) 49.2 ± 1347 ± 1846 ± 15ns
 Living donor (n, %)1/9%3/30%1/22%ns
 Gender (male, %)6/54%3/30%6/66%ns
 HLA mismatches 3 ± 14 ± 12 ± 1ns
 Peak level of PRA 5 ± 744 ± 401 ± 1ns
 CMV serostatus
  D−/R− 1/9%1/10%1/11%ns
  D−/R+ 1/9%1/10%1/11%ns
  D+/R− 3/27%1/10%1/11%ns
  D+/R+ 6/54%7/70%6/66%ns
 Dialysis before TX (months)19 ± 1027 ± 1532 ± 26ns

At 3M biopsy
 Time after TX94.8 ± 5.8343 ± 26885.6 ± 13.5ns
 BMI (kg/m2)23.5 ± 4.827.3 ± 4.327.2 ± 4.7ns
 Immunosuppression
  Induction36%50%44%ns
  Tacrolimus73%80%89%ns
  Cyclosporin A27%0%0ns
  mTOR18%40%11%ns
  Mycophenolate mofetil55%70%89%ns
  Prednisone73%90%89%ns
  CIT (deceased donor) 20 ± 313 ± 919 ± 3ns
  Serum creatinine (μmol/L) 112 ± 60.3210 ± 67.2126 ± 35.3 **
  Serum creatinine at 36-month followup122.6 ± 37.3NA144.1 ± 69.5ns

Data shown as mean ± standard deviation if not indicated otherwise. ESRD: end-stage renal disease; CIT: cold ischemia time; PRA: panel reactive antibody; BMI: body mass index; TX: transplantation; **( ) BKVN versus negative control group; ns: not significant; *P values for categorical data or Fisherś test and for continuous variables Mann-Whitney U test (Student’s t-test where appropriate).